SCHEMBL3079241

SCHEMBL3079241

COCCCc1nc2cccc(C(=O)OC)c2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
GAA P10253 2/20 0.43
PKM P14618 1/20 0.43
LMNA P02545 2/20 0.41
KDM4E B2RXH2 4/20 0.40
RIPK1 Q13546 1/20 0.40
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
THRB P10828 1/20 0.38
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
HTT P42858 2/20 0.37
POLB P06746 2/20 0.37
PKN1 Q16512 1/20 0.37
PKN2 Q16513 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9197306 0.89 RIPK1 (0.48) MAPTGAAPKMLMNAKDM4E
SCHEMBL1917771 0.86 RIPK1 (0.44) MAPTGAALMNAKDM4ERIPK1
SCHEMBL29261995 0.84 CHRM1 (0.53) MAPTGAALMNAKDM4EKMT2A
SCHEMBL29894060 0.84 CHRM1 (0.53) MAPTGAALMNAKDM4EKMT2A
SCHEMBL7721019 0.83 DDAH1 (0.44) MAPTGAALMNAKDM4ERIPK1
SCHEMBL7002080 0.82 KDM4E (0.48) MAPTGAAPKMLMNAKDM4E
SCHEMBL937977 0.81 PKM (0.48) MAPTGAAPKMLMNAKDM4E
SCHEMBL1552358 0.79 RNASEH1 (0.54) MAPTGAAPKMKDM4ETSHR
SCHEMBL20594099 0.79 MAPT (0.46) MAPTGAALMNAKDM4ERIPK1
SCHEMBL10691303 0.77 POLB (0.46) GAAPKMKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012055-A1 Organic compounds REN, ACE, ACE2 MAPT 2397/4885GAA 92/4885PKM 846/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 MAPT 2397/4885GAA 92/4885PKM 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.